Cerecor is advancing its clinical-stage pipeline of innovative therapies for rare and orphan diseases, including congenital disorders of glycosylation and complex lymphatic malformations. They are also developing monoclonal antibodies for severe pediatric-onset Crohn's disease, COVID-19 acute respiratory distress syndrome, Still's disease, systemic juvenile idiopathic arthritis, and multiple myeloma. Their drugs have received Orphan Drug Designation and Rare Pediatric Disease Designation, making them eligible for a priority review voucher upon FDA approval. Founded in 2011, Cerecor aims to become a leader in the development of drugs for neurological and psychiatric disorders.